Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 7/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | GIPR | P48546 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23486294 | 0.86 | RAB9A (0.42) | KMT2AMEN1L3MBTL1RAB9AMAPT | |
| SCHEMBL23460135 | 0.82 | GRM1 (0.49) | KMT2AMEN1L3MBTL1RAB9AMAPT | |
| SCHEMBL7471959 | 0.77 | KMT2A (0.54) | KMT2AMEN1L3MBTL1RAB9AMAPT | |
| SCHEMBL1474111 | 0.74 | RAB9A (0.63) | KMT2AMEN1RAB9AMAPTGRM1 | |
| SCHEMBL23460217 | 0.72 | RAB9A (0.44) | KMT2AMEN1L3MBTL1RAB9AMAPT | |
| SCHEMBL29983701 | 0.72 | KMT2A (0.46) | KMT2AMEN1RAB9AMAPTGSTO1 | |
| SCHEMBL1746924 | 0.72 | KMT2A (0.52) | KMT2AMEN1L3MBTL1RAB9AMAPT | |
| SCHEMBL23460184 | 0.72 | RAB9A (0.49) | KMT2AMEN1L3MBTL1RAB9AMAPT | |
| SCHEMBL23460116 | 0.72 | KDM4E (0.57) | KMT2AMEN1RAB9AMAPTGRM1 | |
| SCHEMBL23486303 | 0.71 | RAB9A (0.51) | KMT2AMEN1L3MBTL1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-4069697-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021113263-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | CRHR1, CRH, CRHR2 | KMT2A 4183/4885MEN1 1248/4885L3MBTL1 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.